Brokerages Anticipate Teladoc Inc (TDOC) to Post -$0.38 EPS

Equities analysts expect that Teladoc Inc (NYSE:TDOC) will post earnings per share of ($0.38) for the current quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Teladoc’s earnings. The highest EPS estimate is ($0.31) and the lowest is ($0.49). Teladoc reported earnings of ($0.28) per share in the same quarter last year, which would indicate a negative year over year growth rate of 35.7%. The firm is scheduled to report its next earnings results after the market closes on Wednesday, August 1st.

According to Zacks, analysts expect that Teladoc will report full year earnings of ($1.45) per share for the current year, with EPS estimates ranging from ($1.68) to ($1.27). For the next year, analysts anticipate that the company will post earnings of ($0.98) per share, with EPS estimates ranging from ($1.41) to ($0.33). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Teladoc.

Teladoc (NYSE:TDOC) last announced its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The business had revenue of $89.64 million during the quarter, compared to analysts’ expectations of $86.77 million. During the same period in the prior year, the company earned ($0.30) earnings per share. The business’s revenue was up 109.0% compared to the same quarter last year.

A number of equities research analysts have recently commented on the stock. Canaccord Genuity upped their target price on shares of Teladoc from $47.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, June 5th. Craig Hallum raised shares of Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. Robert W. Baird increased their price target on shares of Teladoc from $50.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Teladoc to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, June 5th. Finally, MED increased their price target on shares of Teladoc to $56.00 and gave the stock a “hold” rating in a report on Thursday, June 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Teladoc presently has an average rating of “Buy” and an average target price of $55.74.

In other Teladoc news, President Peter A. Mcclennen sold 91,072 shares of the stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $65.84, for a total value of $5,996,180.48. Following the completion of the transaction, the president now directly owns 61,660 shares of the company’s stock, valued at $4,059,694.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Mark Hirschhorn sold 69,460 shares of the stock in a transaction dated Wednesday, May 2nd. The shares were sold at an average price of $43.73, for a total transaction of $3,037,485.80. Following the completion of the transaction, the vice president now directly owns 50,042 shares of the company’s stock, valued at $2,188,336.66. The disclosure for this sale can be found here. Insiders have sold 316,371 shares of company stock valued at $18,552,540 over the last three months. 3.95% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of TDOC. Bank of New York Mellon Corp increased its holdings in Teladoc by 63.0% in the fourth quarter. Bank of New York Mellon Corp now owns 465,917 shares of the health services provider’s stock valued at $16,237,000 after buying an additional 180,129 shares in the last quarter. Geode Capital Management LLC increased its holdings in Teladoc by 16.4% in the fourth quarter. Geode Capital Management LLC now owns 428,312 shares of the health services provider’s stock valued at $14,926,000 after buying an additional 60,205 shares in the last quarter. Guggenheim Capital LLC purchased a new position in Teladoc in the fourth quarter valued at about $272,000. Raymond James & Associates increased its holdings in Teladoc by 3.2% in the fourth quarter. Raymond James & Associates now owns 115,713 shares of the health services provider’s stock valued at $4,033,000 after buying an additional 3,589 shares in the last quarter. Finally, Teachers Advisors LLC increased its holdings in Teladoc by 75.9% in the fourth quarter. Teachers Advisors LLC now owns 722,234 shares of the health services provider’s stock valued at $25,170,000 after buying an additional 311,591 shares in the last quarter.

Shares of NYSE:TDOC traded down $2.05 on Monday, reaching $63.85. The company’s stock had a trading volume of 1,275,815 shares, compared to its average volume of 1,135,994. Teladoc has a 52-week low of $27.30 and a 52-week high of $71.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.15 and a current ratio of 4.15. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of -38.70 and a beta of 0.41.

About Teladoc

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Investing in Growth Stocks

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply